If Novavax is successful, it could generate billions.
News & Analysis: Novavax
Human trials of the combination vaccine are expected to start later this year.
The European Commission president has provided some hints that a supply agreement with Novavax could be on the way.
An analyst's price target cut reflected an uncomfortable new reality for the biotech.
It had nothing to do with the company's financial performance.
The company's latest coronavirus vaccine news produced an unpleasant side effect.
The danger is overstated.
It may offer key COVID program updates.
Showered with optimism in April, shareholders will have to wait for the bloom.
Find out what was responsible for the Nasdaq missing out on gains.